Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Scientists devise safer way to create iPS cells

Researchers at Johns Hopkins have found a better way to create induced pluripotent stem (iPS) cells-adult cells reprogrammed with the properties of embryonic stem cells-from a small blood sample. This new method, described last week in Cell Research, avoids creating DNA changes that could lead to tumor formation.

1 Feb 2011

$FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma$

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma.

1 Feb 2011

IDEXX Laboratories fourth quarter revenues increase 5% to $283.8 million

IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2010 increased 5% to $283.8 million, from $270.3 million for the fourth quarter of 2009. Organic revenue growth, as defined below, was 6%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2010 increased 22% to $0.62, compared to $0.51 for the same period in the prior year.

28 Jan 2011

Study suggests newborn diagnosis can improve survival in SCID patients

Severe Combined Immunodeficiency occurs in just one out of every 50,000 to 100,000 births in the United States, yet it is the most serious primary immunodeficiency disorder. A study published today in Blood, the Journal of the American Society of Hematology, demonstrates that babies with SCID who are diagnosed at birth and receive a hematopoietic stem cell transplant, which is the transplantation of blood-forming stem cells, have significantly improved survival.

28 Jan 2011

API2-MALT1 fusion protein appears to trigger cancer

What happens when two proteins join together? In this case, they become like a power couple, where the whole is greater than the sum of the parts. API2 and MALT1 are two proteins that become fused together in a subset of lymphomas. The API2 part of the fusion connects with an enzyme called NIK. When it does, MALT1 comes in for the kill, splitting NIK in two, a process called cleavage.

28 Jan 2011

HIV causes specific subset of CD4+ T-cells to age rapidly: Study

In the early years of the AIDS epidemic, being infected with the virus that causes the disease was considered a virtual death sentence. But with the development of antiretroviral therapy, many with HIV are now living much longer. In fact, it is estimated that by 2015, about half of all HIV-positive individuals will be older than 50.

28 Jan 2011

Baxter fourth quarter net income declines 26% to $423 million

Baxter International Inc. today announced its financial results for the fourth quarter of 2010, and provided its financial outlook for the first quarter and full-year 2011.

From Baxter International Inc. 27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.

25 Jan 2011

IRIS International places 40 iQ200 Elite Automated Urine Microscopy Analyzers in Mexico in 2010

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory,has begun to significantly penetrate the Mexican healthcare market with the initial placement in 2010 of 40 iQ®200 Elite™ Automated Urine Microscopy Analyzers within one of the largest social security healthcare systems in Mexico.

25 Jan 2011

Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Colon Cancer test

Genomic Health, Inc. today announced presentation of three studies at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, including one finding that high tumor grade was not a marker of higher recurrence risk in stage II colon cancer, suggesting that other markers, such as the Oncotype DX® Recurrence Score® (RS) test as well as T-stage and mismatch repair (MMR) status, should be considered by physicians during the treatment decision-making process.

25 Jan 2011

Breast and lung cancer: Shared risk and treatment

New research has shown that women who are heavy smokers before menopause, especially prior to giving birth, may significantly increase their risk of developing breast cancer. In the US study looking at almost 150,000 women from the Nurses’ Health Study; it was found that breast cancer rates increased with higher levels of smoking among younger age groups. The study appeared in the journal Archives of Internal Medicine.

24 Jan 2011

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Bayer HealthCare Pharmaceuticals Inc. announced today that the Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously that clinical trial and postmarketing data for gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product for proposed use in diagnostic magnetic resonance imaging (MRI) in adults and children.

24 Jan 2011

Researchers take systematic approach to catalog factors that control blood cell development

A small pool of stem cells replenishes the human body with about 200 billion new blood cells daily. But the elaborate circuitry that determines if a cell will develop into a T cell, red blood cell, or one of the nine or more other blood cell types remains largely unknown. A research team led by scientists from the Broad Institute and Brigham and Women's Hospital has taken a systematic approach to help decipher this circuitry, compiling a comprehensive catalog of the factors that determine a blood cell's fate.

21 Jan 2011

Positive results from nimotuzumab Phase II study for gastric cancer

YM BioSciences, a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.

21 Jan 2011

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

20 Jan 2011

Message of health benefits of moderate drinking are hazardous and extremely dangerous

A Letter to the Editor entitled "What should we advise about alcohol consumption?" was recently published by Maurizio Ponz de Leon in Intern Emerg Med.1 Dr. de Leon argues that the message of health benefits of moderate drinking "seems to me hazardous and extremely dangerous to diffuse in the general population."

20 Jan 2011

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUS study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy.

19 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

RAS includes Merge iConnect solution

Merge Healthcare, a leading health IT solutions provider, today announced that Radiology Associates of Sacramento (RAS), the largest private radiology practice in Northern California, has expanded their Merge solution suite to include Merge iConnect.

12 Jan 2011

Hematology News and Research

Further Reading

Scientists devise safer way to create iPS cells

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

IDEXX Laboratories fourth quarter revenues increase 5% to $283.8 million

Study suggests newborn diagnosis can improve survival in SCID patients

API2-MALT1 fusion protein appears to trigger cancer

HIV causes specific subset of CD4+ T-cells to age rapidly: Study

Baxter fourth quarter net income declines 26% to $423 million

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

IRIS International places 40 iQ200 Elite Automated Urine Microscopy Analyzers in Mexico in 2010

Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Colon Cancer test

Breast and lung cancer: Shared risk and treatment

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Researchers take systematic approach to catalog factors that control blood cell development

Positive results from nimotuzumab Phase II study for gastric cancer

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Message of health benefits of moderate drinking are hazardous and extremely dangerous

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

RAS includes Merge iConnect solution

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News